Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

New premium system features help improve workflow and deliver clinical confidence

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

November 16, 2018 — Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new premium magnetic resonance imaging (MRI) system, Vantage Orian 1.5T. The Vantage Orian represents a new standard in the premium wide bore 1.5T market, according to Canon, with new technology designed to boost productivity, enhance patient comfort and deliver diagnostic clinical confidence.

The new system and its features to enhance workflow will be showcased at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.

With a new slim gradient that delivers a gradient performance with a maximum amplitude of 45 mT/m, combined with a slew rate of 200 T/m/s that enhances high resolution and diffusion imaging, Vantage Orian offers high performance imaging capability previously not available on 1.5T systems from Canon Medical Systems.

Utilizing migrated high end 3T technology, Vantage Orian offers referring physicians and patients diagnostic MRI imaging services with complete clinical confidence. Canon Medical System’s PURERF and Saturn Gradient technology means that stable and consistent imaging performance is ensured, increasing signal to noise ratio (SNR) by up to 38 percent.

The Vantage Orian offers a range of new Rapid Scan and Easy Tech technology that reduces scan time and helps improve workflow. A redesigned gantry interface and dockable table ensure seamless patient handling. New applications like Multiband SPEEDER, that shortens acquisitions such as high angular resolution diffusion imaging (HARDI), and up to eight times accelerated k-t SPEEDER allows high-frame-rate cardiac cine and perfusion imaging with free breathing.

Vantage Orian also offers one of the smallest footprints in the 1.5T wide-bore class, according to Canon, and low power consumption eco features that reduce energy use by up to 21 percent. The system is equipped with maintenance programs to satisfy the needs of hospital administrators.

A relaxed patient is key in MRI, and Vantage Orian takes care of this with quiet scan sequences that reduce ambient noise by Pianissimo Zen technology. The 71cm wide bore and immersive virtual MR Theater are designed to put patients at ease. Vantage Orian also addresses challenging patients with Pediatric SPEEDER coils, contrast-free applications and ForeSee View for simplified scan planning.

For more information: www.us.medical.canon

Related Content

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020
October 27, 2020 – Magn...
Ceiling-mounted X-ray system includes MyExam Companion intelligent user interface to guide technologist through exam workflow
News | X-Ray | October 26, 2020
October 26, 2020 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...